Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, has launched its new analytical platform, LabZient: a standardized and automated platform designed to streamline the assessment and validation of large molecules, thereby reducing drug development timelines and resource costs.   LabZient aims to combine predictive in-silico evaluation with established and vetted laboratory methods that de-risk the application of platform analytical procedures. In doing so, LabZient ...